John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at john@fiercemarkets.com. Follow @JohnCFierce on Twitter.

Articles by John Carroll

Antigenics shares gain on GSK's ambitious PhIII vax program

GlaxoSmithKline isn't the only company cheering this week's launch of a late-stage program for a shingles vaccine. Antigenics flagged its own role in the parade for the potential blockbuster and was

Feds earmark $2B for new, faster vaccine tech

U.S. health officials have taken some of the lessons they learned during the swine flu pandemic to heart. And now they're taking action to prevent a recurrence of crucial problems that slowed vaccine

MRSA vax breakthrough reported by UChicago team

With the deadly MRSA bacteria making the rounds at hospitals with increasing frequency, investigators have highlighted two new research developments that could help pave the way to a new vaccine for

Critics deride WHO's ties to vaccine industry

Five of the 15 experts who sat on the WHO's emergency swine flu panel had financial ties to the drug industry, stirring fresh accusations that the group helped spur huge profits for drug companies

Selecta gets a new CEO, $3M for nicotine vax program

Selecta Biosciences has turned to a veteran of the pharma world to lead it through the startup phase. Werner Cautreels, who helmed Solvay Pharmaceuticals through its $6.6 billion sale to Abbott in

WHO says H1N1 pandemic has run its course

The swine flu virus will be with us indefinitely, but the World Health Organization says that the H1N1 pandemic it triggered is over. For the vaccine industry, the pandemic presented an opportunity

Team tackles therapeutic Parkinson's vax

Investigators engaged in preclinical studies have already seen how blocking a particular protein can reduce the level of nerve damage associated with Parkinson's disease. Now researchers at the

Emergent forms JV for new pandemic vaccine

Rockville, MD-based Emergent BioSolutions has reached halfway around the world to join hands with a new partner to quickly develop a broad spectrum pandemic vaccine against multiple H5 strains.

Crucell forges ahead with combo AIDS vax trial

Joining with a host of collaborators, Crucell plans to take a promising combo approach for a new AIDS vaccine into the clinic in the U.S. in an ambitious effort to forge ahead on one of the most

Manufacturers get an early start on flu vax shipments

Vaccine manufacturers have begun to deliver huge shipments of the new seasonal flu vaccine ahead of schedule. This year's shot protects against two strains of seasonal flu as well as H1N1, doing away